Telavancin: A Review of its Use in Treating Gram-Positive Infections

Telavancin is a lipoglycopeptide antibiotic with a dual mechanism of action; it disrupts both cell wall synthesis and cell membrane integrity resulting in rapid bactericidal activity. It is active against a wide range of Gram-positive organisms, including methicillin-resistant, vancomycin-intermediate, linezolid-resistant and daptomycin-resistant Staphylococcus aureus strains. Resistance is uncommon and only occurs in vancomycin-resistant organisms of the VanA type. Its pharmacokinetic profile enables once daily administration, making it potentially suitable for use in the outpatient setting. Telavancin is renally excreted and requires dose adjustment in renal impairment. Clinical trials have demonstrated efficacy in the treatment of complicated skin and skin structure infections and nosocomial pneumonia caused by Gram-positive pathogens. This review outlines the mechanisms of action, antimicrobial spectrum, pharmacokinetics, clinical use and safety aspects of telavancin, and discusses its potential role in the antimicrobial armamentarium.

[1]  J. Janc,et al.  Effects of telavancin on coagulation test results , 2011, International journal of clinical practice.

[2]  R. Danesi,et al.  Case Report of a Successful Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia and MRSA/Vancomycin-Resistant Enterococcus faecium Cholecystitis by Daptomycin , 2011, Antimicrobial Agents and Chemotherapy.

[3]  M. Niederman,et al.  Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  D. Paterson,et al.  Systematic Review and Meta-Analysis of the Significance of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates , 2010, Antimicrobial Agents and Chemotherapy.

[5]  K. Krause,et al.  In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies. , 2010, Diagnostic microbiology and infectious disease.

[6]  B. Camins,et al.  Successful Treatment of Vancomycin-Intermediate Staphylococcus aureus Pacemaker Lead Infective Endocarditis with Telavancin , 2010, Antimicrobial Agents and Chemotherapy.

[7]  J. Shaw,et al.  Single‐Dose Pharmacokinetics and Tolerability of Telavancin in Elderly Men and Women , 2010, Pharmacotherapy.

[8]  R. Seaton,et al.  Outpatient parenteral antimicrobial therapy: Recent developments and future prospects. , 2010, Current opinion in investigational drugs.

[9]  Ronald N. Jones,et al.  Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia. , 2010, The Journal of antimicrobial chemotherapy.

[10]  Stephanie R Hartouni,et al.  Fluorescence Microscopy Demonstrates Enhanced Targeting of Telavancin to the Division Septum of Staphylococcus aureus , 2010, Antimicrobial Agents and Chemotherapy.

[11]  S. Barriere,et al.  Effect of Telavancin on the Pharmacokinetics of the Cytochrome P450 3A Probe Substrate Midazolam: A Randomized, Double‐Blind, Crossover Study in Healthy Subjects , 2010, Pharmacotherapy.

[12]  J. Shaw,et al.  Lack of Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Telavancin , 2010, Pharmacotherapy.

[13]  G. Stein,et al.  Telavancin: a novel lipoglycopeptide. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  S. Finegold,et al.  In Vitro Activities of Telavancin and Six Comparator Agents against Anaerobic Bacterial Isolates , 2009, Antimicrobial Agents and Chemotherapy.

[15]  M. Kinzig,et al.  Lack of Pharmacokinetic Drug Interactions Following Concomitant Administration of Telavancin with Aztreonam or Piperacillin/Tazobactam in Healthy Participants , 2009, Journal of clinical pharmacology.

[16]  S. Wilson,et al.  Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures. , 2009, American journal of surgery.

[17]  M. Mammen,et al.  Telavancin Disrupts the Functional Integrity of the Bacterial Membrane through Targeted Interaction with the Cell Wall Precursor Lipid II , 2009, Antimicrobial Agents and Chemotherapy.

[18]  L. Mermel,et al.  In Vitro Activities of Telavancin and Vancomycin against Biofilm-Producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis Strains , 2009, Antimicrobial Agents and Chemotherapy.

[19]  J. Calhoun,et al.  Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model. , 2008, The Journal of antimicrobial chemotherapy.

[20]  P. Appelbaum,et al.  Postantibiotic Effects of Telavancin against 16 Gram-Positive Organisms , 2008, Antimicrobial Agents and Chemotherapy.

[21]  M. Goldberg,et al.  Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. , 2008, The Journal of antimicrobial chemotherapy.

[22]  K. Krause,et al.  In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. , 2008, The Journal of antimicrobial chemotherapy.

[23]  R. Moellering,et al.  Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  V. Fowler,et al.  Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  K. Krause,et al.  Comparative Surveillance Study of Telavancin Activity against Recently Collected Gram-Positive Clinical Isolates from across the United States , 2008, Antimicrobial Agents and Chemotherapy.

[26]  K. Krause,et al.  In Vitro Activity of Telavancin against Resistant Gram-Positive Bacteria , 2008, Antimicrobial Agents and Chemotherapy.

[27]  J. Shaw,et al.  Intrapulmonary Distribution of Intravenous Telavancin in Healthy Subjects and Effect of Pulmonary Surfactant on In Vitro Activities of Telavancin and Other Antibiotics , 2007, Antimicrobial Agents and Chemotherapy.

[28]  L. Friedrich,et al.  Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. , 2007, The Journal of antimicrobial chemotherapy.

[29]  L. Saravolatz,et al.  Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus. , 2007, The Journal of antimicrobial chemotherapy.

[30]  V. Fowler,et al.  Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 Study , 2006, Antimicrobial Agents and Chemotherapy.

[31]  J. Shaw,et al.  Tissue Penetration of Telavancin after Intravenous Administration in Healthy Subjects , 2006, Antimicrobial Agents and Chemotherapy.

[32]  A. Stucki,et al.  Efficacy of Telavancin against Penicillin-Resistant Pneumococci and Staphylococcus aureus in a Rabbit Meningitis Model and Determination of Kinetic Parameters , 2006, Antimicrobial Agents and Chemotherapy.

[33]  H. Chambers,et al.  Efficacy of Telavancin in a Rabbit Model of Aortic Valve Endocarditis Due to Methicillin-Resistant Staphylococcus aureus or Vancomycin-Intermediate Staphylococcus aureus , 2005, Antimicrobial Agents and Chemotherapy.

[34]  V. Fowler,et al.  Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  D. Snydman,et al.  Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  Deborah L. Higgins,et al.  Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus , 2005, Antimicrobial Agents and Chemotherapy.

[37]  Deborah L. Higgins,et al.  Pharmacokinetics, Serum Inhibitory and Bactericidal Activity, and Safety of Telavancin in Healthy Subjects , 2005, Antimicrobial Agents and Chemotherapy.

[38]  E. Goldstein,et al.  In Vitro Activities of the New Semisynthetic Glycopeptide Telavancin (TD-6424), Vancomycin, Daptomycin, Linezolid, and Four Comparator Agents against Anaerobic Gram-Positive Species and Corynebacterium spp , 2004, Antimicrobial Agents and Chemotherapy.

[39]  M. Kaufmann,et al.  Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. , 2002, The Journal of antimicrobial chemotherapy.